These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

70 related articles for article (PubMed ID: 2991619)

  • 21. Human T-lymphotropic retrovirus type III (HTLV-III) in Danish homosexuals.
    Lange Wantzin G; Saxinger WC; Weismann K; Gallo RC
    Acta Derm Venereol; 1985; 65(3):247-50. PubMed ID: 2411083
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Retrovirus and malignant lymphoma in homosexual men.
    Levine AM; Gill PS; Meyer PR; Burkes RL; Ross R; Dworsky RD; Krailo M; Parker JW; Lukes RJ; Rasheed S
    JAMA; 1985 Oct; 254(14):1921-5. PubMed ID: 2995692
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Update: Public Health Service workshop on human T-lymphotropic virus type III antibody testing--United States.
    Centers for Disease Control (CDC)
    MMWR Morb Mortal Wkly Rep; 1985 Aug; 34(31):477-8. PubMed ID: 2991728
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Human T-cell lymphotropic virus type III infection in a cohort of homosexual men in New York City.
    Stevens CE; Taylor PE; Zang EA; Morrison JM; Harley EJ; Rodriguez de Cordoba S; Bacino C; Ting RC; Bodner AJ; Sarngadharan MG
    JAMA; 1986 Apr; 255(16):2167-72. PubMed ID: 3007789
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Update on hepatitis B prevention. Recommendations of the Immunization Practices Advisory Committee. Centers for Disease Control, Department of Health and Human Services.
    Ann Intern Med; 1987 Sep; 107(3):353-7. PubMed ID: 3039889
    [TBL] [Abstract][Full Text] [Related]  

  • 26. HTLV and immunosuppression.
    Essex M; Kanki P; Allan J; Barin F; McLane MF; Lee TH; Kitchen L; Homma T; Malone G; Yokota T
    Princess Takamatsu Symp; 1984; 15():309-18. PubMed ID: 6100649
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Relation of HTLV-III seropositivity and lymphadenopathy.
    Jeffries E; Boyko WJ; Willoughby B; Constance PD; Wiggs B; O'Shaughnessy M; Sharp FR
    Can Med Assoc J; 1985 Jul; 133(2):111-2. PubMed ID: 2988732
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Licensed tests for antibody to human T-lymphotropic virus type III. Sensitivity and specificity.
    Petricciani JC
    Ann Intern Med; 1985 Nov; 103(5):726-9. PubMed ID: 2996408
    [TBL] [Abstract][Full Text] [Related]  

  • 29. HTLV-III AIDS link.
    Bennett JA
    Am J Nurs; 1985 Oct; 85(10):1086-9. PubMed ID: 2996353
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mechanisms of B cell activation in patients with acquired immunodeficiency syndrome and related disorders. Contribution of antibody-producing B cells, of Epstein-Barr virus-infected B cells, and of immunoglobulin production induced by human T cell lymphotropic virus, type III/lymphadenopathy-associated virus.
    Yarchoan R; Redfield RR; Broder S
    J Clin Invest; 1986 Aug; 78(2):439-47. PubMed ID: 3016028
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The prospects for and pathways toward a vaccine for AIDS.
    Francis DP; Petricciani JC
    N Engl J Med; 1985 Dec; 313(25):1586-90. PubMed ID: 2999596
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Retroviruses associated with leukemia and ablative syndromes in animals and in human beings.
    Essex M; McLane MF; Kanki P; Allan J; Kitchen L; Lee TH
    Cancer Res; 1985 Sep; 45(9 Suppl):4534s-4538s. PubMed ID: 2990682
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Increase in the prevalence of antibodies against LAV/HTLV III in drug addicts in West Germany].
    Zoulek G; Gürtler L; Eberle J; Lorbeer B; Deinhardt F
    Dtsch Med Wochenschr; 1986 Apr; 111(15):567-70. PubMed ID: 3007065
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Human T-cell lymphotropic virus type III associated disorders. The spectrum in the heterosexual population.
    Gill PS; Levine AM; Meyer PR; Aguilar SL; Rarick M; Parker JW; Rasheed S
    Arch Intern Med; 1986 Aug; 146(8):1501-4. PubMed ID: 3015064
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Should the risk of acquired immunodeficiency syndrome deter hepatitis B vaccination? A decision analysis.
    Sacks HS; Rose DN; Chalmers TC
    JAMA; 1984 Dec; 252(24):3375-7. PubMed ID: 6239044
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Safety of therapeutic immune globulin preparations with respect to transmission of human T-lymphotropic virus type III/lymphadenopathy-associated virus infection.
    Centers for Disease Control (CDC)
    MMWR Morb Mortal Wkly Rep; 1986 Apr; 35(14):231-3. PubMed ID: 3007971
    [No Abstract]   [Full Text] [Related]  

  • 37. AIDS update: HTLV-III testing, immune globulins and employees with AIDS.
    Valenti WM
    Infect Control; 1986 Aug; 7(8):427-30. PubMed ID: 3017881
    [No Abstract]   [Full Text] [Related]  

  • 38. AIDS virus antibody in polytransfused dialysis patients vaccinated against hepatitis B.
    Desmyter J; Reynders M; Goubau P
    Br Med J (Clin Res Ed); 1986 Aug; 293(6546):537. PubMed ID: 3019458
    [No Abstract]   [Full Text] [Related]  

  • 39. The safety of the hepatitis B vaccine.
    Meric AL
    JAMA; 1987 Jan; 257(3):315-6. PubMed ID: 2948031
    [No Abstract]   [Full Text] [Related]  

  • 40. Intravenous drug abuse and the accident and emergency department: AIDS (HTLV-III) antibodies and hepatitis B markers.
    Dunlop MG; Steedman DJ; Peutherer JF
    Arch Emerg Med; 1986 Dec; 3(4):257-9. PubMed ID: 3026414
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.